OHR Pharmaceutical Inc (NASDAQ:OHRP), a clinical-stage biotechnology company developing novel therapies for ophthalmic diseases, today announced that it has reached an agreement on the …
OHR Pharmaceutical Inc (NASDAQ:OHRP), an ophthalmology research and development company, today announced positive results from a preclinical study investigating its proprietary SKS sustained …
OHR Pharmaceutical Inc (NASDAQ:OHRP), an ophthalmology research and development company, today announced positive results from a preclinical study investigating its proprietary SKS sustained release …
OHR Pharmaceutical Inc (NASDAQ:OHRP), an ophthalmology research and development company, presented additional positive data from the Phase 2 IMPACT study evaluating OHR-102 (Squalamine lactate …
Brean Capital analyst Jonathan Aschoff came out today with some commentary on OHR Pharmaceutical Inc (NASDAQ:OHRP), after the company reported initial, encouraging data for the treatment of …
OHR Pharmaceutical Inc (NASDAQ:OHRP) shares have taken off, adding 44.05% to trade at $3.
Groupon Inc (NASDAQ:GRPN) shares rose 3.3% in pre-market trading to $5.
The first quarter of 2015 has come to a close and companies are still releasing earnings reports. Let’s look back and see which …
OHR Pharmaceutical Inc (NASDAQ:OHRP) shares plunged nearly 70% today after the company announced topline results from its exploratory phase II IMPACT study testing OHR-102 in combination with Lucentis …
In a research note published after market close today, Chardan Capital analyst Gbola Amusa maintained a Neutral rating on OHR Pharmaceutical Inc (NASDAQ:OHRP) and reduced …
